PE20160218A1 - Metodos para controlar los niveles de fucosilacion en proteinas - Google Patents

Metodos para controlar los niveles de fucosilacion en proteinas

Info

Publication number
PE20160218A1
PE20160218A1 PE2016000087A PE2016000087A PE20160218A1 PE 20160218 A1 PE20160218 A1 PE 20160218A1 PE 2016000087 A PE2016000087 A PE 2016000087A PE 2016000087 A PE2016000087 A PE 2016000087A PE 20160218 A1 PE20160218 A1 PE 20160218A1
Authority
PE
Peru
Prior art keywords
fucosilation
proteins
methods
control levels
eukaryotic
Prior art date
Application number
PE2016000087A
Other languages
English (en)
Inventor
Harish Venkatraman Pai
Saravanan Desan
Kriti Shukla
Sunaina Prabhu
Laxmi Adhikary
Rasika Venkataraman
Ramakrishnan Melarkode
Pradip Nair
Casimiro Jose Enrique Montero
Dinesh Baskar
Ankur Bhatnagar
Original Assignee
Biocon Ltd
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Centro Inmunologia Molecular filed Critical Biocon Ltd
Publication of PE20160218A1 publication Critical patent/PE20160218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invencion se relaciona con un metodo o procedimiento para controlar, inhibir o reducir la fucosilacion de proteinas en un eucariota y/o sistema de expresion de proteinas eucariota. Dicho metodo comprende llevar a cabo la expresion de proteina y/o modificacion post-traduccional en presencia de una elevada concentracion de manganeso o de iones de manganeso
PE2016000087A 2013-07-23 2014-07-23 Metodos para controlar los niveles de fucosilacion en proteinas PE20160218A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3265CH2013 2013-07-23
IN3262CH2013 2013-07-23

Publications (1)

Publication Number Publication Date
PE20160218A1 true PE20160218A1 (es) 2016-05-09

Family

ID=52392808

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000087A PE20160218A1 (es) 2013-07-23 2014-07-23 Metodos para controlar los niveles de fucosilacion en proteinas

Country Status (19)

Country Link
US (2) US9856502B2 (es)
EP (2) EP3024922A4 (es)
JP (1) JP6480926B2 (es)
KR (1) KR102062784B1 (es)
CN (1) CN105392878A (es)
AU (1) AU2014294618B2 (es)
BR (1) BR112016001461A2 (es)
CA (1) CA2926967C (es)
CU (1) CU24312B1 (es)
EA (1) EA201690269A1 (es)
HK (1) HK1220228A1 (es)
MX (1) MX2016001042A (es)
NZ (1) NZ716182A (es)
PE (1) PE20160218A1 (es)
PH (1) PH12016500158A1 (es)
SG (1) SG11201600067YA (es)
TW (1) TWI621711B (es)
WO (1) WO2015011660A1 (es)
ZA (1) ZA201601113B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089919A1 (en) * 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CA3039855A1 (en) * 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
US11530403B2 (en) * 2016-11-18 2022-12-20 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
EA202092286A1 (ru) * 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
EP3833688A1 (en) * 2018-08-10 2021-06-16 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
HUP1800376A2 (hu) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
BR112021008879A2 (pt) * 2018-11-13 2021-10-26 Janssen Biotech, Inc. Controle de oligometais durante a produção de anticorpos anti-cd38
JP7469593B2 (ja) 2018-12-27 2024-04-17 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体を製造する方法
CN112779307B (zh) * 2021-01-11 2022-04-19 苏州药明生物技术有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
US20030204862A1 (en) 2002-03-05 2003-10-30 Ralf Kuehn Inbred embryonic stem-cell derived mice
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
CA2630811C (en) 2005-12-08 2016-05-31 Amgen Inc. Improved production of glycoproteins using manganese
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2993186B1 (en) * 2008-03-14 2019-09-04 Biocon Limited A monoclonal antibody and a method thereof
US20120277165A1 (en) * 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
MX2012011648A (es) * 2010-04-07 2012-11-29 Momenta Pharmaceuticals Inc Glicanos de alta manosa.
WO2013114245A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition

Also Published As

Publication number Publication date
US20160138065A1 (en) 2016-05-19
TWI621711B (zh) 2018-04-21
US9856502B2 (en) 2018-01-02
EA201690269A1 (ru) 2016-05-31
PH12016500158A1 (en) 2016-04-25
KR102062784B1 (ko) 2020-01-07
SG11201600067YA (en) 2016-02-26
JP6480926B2 (ja) 2019-03-13
CU24312B1 (es) 2018-02-08
MX2016001042A (es) 2017-01-05
CN105392878A (zh) 2016-03-09
CU20160008A7 (es) 2016-11-29
TW201512396A (zh) 2015-04-01
JP2016525352A (ja) 2016-08-25
KR20160036589A (ko) 2016-04-04
WO2015011660A1 (en) 2015-01-29
EP4282975A3 (en) 2024-02-28
AU2014294618A1 (en) 2016-02-11
ZA201601113B (en) 2017-08-30
EP3024922A1 (en) 2016-06-01
US10308970B2 (en) 2019-06-04
EP4282975A2 (en) 2023-11-29
NZ716182A (en) 2018-07-27
US20180087080A1 (en) 2018-03-29
EP3024922A4 (en) 2017-03-29
AU2014294618B2 (en) 2019-06-27
CA2926967A1 (en) 2015-01-29
BR112016001461A2 (pt) 2017-08-29
HK1220228A1 (zh) 2017-04-28
CA2926967C (en) 2020-12-08

Similar Documents

Publication Publication Date Title
PE20160218A1 (es) Metodos para controlar los niveles de fucosilacion en proteinas
PH12019501931A1 (en) Anti-pdl1 antibody formulations
BR112018004887A2 (pt) sistemas e métodos de controle de potência.
EP3262572A4 (en) Techniques of oscillator control for quantum information processing and related systems and methods
BR112013032042A2 (pt) dispositivos e métodos de recepção e de difusão, programa, sistema de controle do aplicativo de ligação
EP3028100A4 (en) Application specific, dual mode projection system and method
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EP2984346A4 (en) Water booster control system and method
UY34558A (es) Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
BR112014029884A2 (pt) sistemas de controle e método.
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
CL2016000021A1 (es) Combinación herbicida que comprende ácido pelargónico e inhibidores específicos de als
WO2014197885A3 (en) Inhibitors of complement factor h
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
DK3262163T3 (da) Fusariumtoxin spaltende polypeptidvarianter, additiver indeholdende samme og anvendelse af samme samt fremgangsmåde til spaltning af fusariumtoxiner
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
HK1221514A1 (zh) 對通電眼科鏡片進行編程的系統和方法
EP3335825A4 (en) INVISIBLE LASER SYSTEM AND LIGHT PATH VISIBLE PROCESS FOR THIS
EP3696190A3 (en) Methods
WO2014130741A3 (en) Nme inhibitors and methods of using nme inhibitors
CL2015002080A1 (es) Métodos de control selectivo de malezas
EP2991222A4 (en) Switching amplifier and control method therefor
BR112014012315A2 (pt) sistema de controle de um reservatório e procedimento de controle associado
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
TWI484370B (en) Method for controlling sound and light implemented by qr code and application program using for the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal